Research Paper Volume 13, Issue 9 pp 12431—12455
Identification of a mesenchymal-related signature associated with clinical prognosis in glioma
Figure 9. The relative expression of GBM mesenchymal markers and MES protein markers after FCGR2A or EHD2 silencing. (A, B) The relative mRNA expression of CHI3L1 and CD44 after silencing FCGR2A. (C, D) The relative mRNA expression of CHI3L1 and CD44 after silencing EHD2. (E) The western blot analysis of CD44, BMI1, VIM and ZEB1 protein markers after silencing FCGR2A. (F) The western blot analysis of CD44, BMI1, VIM and ZEB1 protein markers after silencing EHD2. Ns: no significance; *P<0.05; **P<0.01; ***P<0.001.